相关实验视频

Updated: Jul 13, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

一种可转换的超分子双特异细胞激活剂,用于增强天然杀伤剂和T细胞基癌症免疫疗法

Yumiao Chen¹, Wei Li¹, Zhongqiu Wang¹

¹State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials, and College of Life Sciences, Nankai University, Tianjin, 300071, P. R. China.

Advanced materials (Deerfield Beach, Fla.)

|October 19, 2023

概括

一种新型的超分子双特异性细胞吸引剂 (Supra-BiCE) 增强了自然杀手 (NK) /T细胞癌症免疫疗法. 它在瘤中转化,改善细胞透和阻断免疫检查点,以获得更大的治疗效果.

科学领域:

免疫学免疫学免疫学
生物技术是生物技术.
在瘤学瘤学.

背景情况:

免疫细胞透和瘤微环境限制了癌症免疫治疗的有效性.
自然杀手 (NK) 和T细胞对于抗癌免疫非常重要.
针对PD-L1和TIGIT等免疫检查点可以增强抗瘤反应.

研究的目的:

开发一种对性酸酶 (ALP) 敏感且可转化的超分子双特异性细胞吸引剂 (Supra-BiCE).
通过增强瘤透和激活免疫细胞,利用NK/T细胞改善癌症免疫疗法.
调查Supra-BiCE针对各种癌症类型的可定制治疗潜力.

主要方法:

通过联合组装化酸SA-P (准PD-L1) 和SA-T (准TIGIT) 来构建Supra-BiCE.
在ALP过度表达瘤中静脉注射Supra-BiCE,观察其自组装成纳米丝带和转化为纳米纤维.
在结肠癌模型中评估Supra-BiCE的结合亲缘关系,NK/T细胞积累,激活和抗瘤功效.

主要成果:

在瘤区域,Supra-BiCE纳米带转化为纳米纤维,增强与PD-L1和TIGIT的结合.
这种转变促进NK/T细胞在瘤中的积累和保留.
通过Supra-BiCE对PD-L1和TIGIT的联合阻断激活了透的NK/T细胞,在结肠癌模型中达到98.27%的瘤抑制,T:P比为1:3.

结论:

Supra-BiCE是吸引NK和T细胞参与癌症免疫疗法的有希望的工具.
响应ALP的转换机制提高了目标交付和有效性.
可调节的比允许针对不同癌症进行量身定制的免疫治疗策略.

关键词:

在T细胞,T细胞.双特异性细胞参与者癌症免疫疗法免疫疗法自然杀手细胞是自然杀手细胞.自组装可以自组装.

更多相关视频

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...